MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-05-2024
Catalent Depreciation & Amortization 2011-2026 | CTLT
Annual Depreciation & Amortization Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 489 M | 422 M | 378 M | 289 M | 254 M | 229 M | 190 M | 146 M | 141 M | 141 M | 143 M | 152 M | 130 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 489 M | 130 M | 239 M |
Quarterly Depreciation & Amortization Catalent
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113 M | - | 126 M | 121 M | 112 M | - | 106 M | 103 M | 99 M | 202 M | 99 M | 98 M | 81 M | 179 M | 76 M | 71 M | 69 M | 140 M | 69.1 M | 61.9 M | 60.6 M | 122 M | 60.6 M | 54.6 M | 52.9 M | 108 M | 52.9 M | 46.8 M | 39 M | 85.8 M | 39 M | 35.5 M | 35.8 M | 71.3 M | 35.8 M | 35.2 M | 35.5 M | 70.7 M | 35.5 M | 35.2 M | 35 M | 70.2 M | 35 M | 37.3 M | 36.5 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 202 M | 35 M | 75.6 M |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | $ 21.64 | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 1.05 | -2.34 % | $ 113 M |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
4.9 M | $ 3.82 | -1.29 % | $ 53.7 M | USA |
 |
DURECT Corporation
DRRX
|
31 K | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
125 M | $ 10.75 | -2.54 % | $ 550 M | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
5.3 M | $ 4.28 | -0.46 % | $ 265 M | USA |
 |
China Pharma Holdings
CPHI
|
2.62 M | $ 0.69 | 7.78 % | $ 12 M |  China |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
Harrow Health
HROW
|
1.06 M | $ 47.33 | -2.73 % | $ 1.54 B | USA |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Bausch Health Companies
BHC
|
1.26 B | $ 5.86 | -3.62 % | $ 2.14 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
3.26 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
13.6 M | $ 3.72 | -1.2 % | $ 490 M | USA |
 |
Pacira BioSciences
PCRX
|
78.8 M | $ 21.5 | -1.08 % | $ 994 M | USA |
 |
Perrigo Company plc
PRGO
|
326 M | $ 14.37 | -1.61 % | $ 1.97 B | USA |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
1.44 M | $ 1.01 | -7.34 % | $ 23.6 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 3.9 | -2.63 % | $ 117 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
28.2 M | $ 12.07 | 0.96 % | $ 857 M | USA |
 |
Tilray
TLRY
|
35.7 M | $ 7.49 | -1.77 % | $ 4.63 B | Canada |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 2.78 | -2.46 % | $ 3.45 M | USA |
 |
Solid Biosciences
SLDB
|
2.46 M | $ 6.15 | -3.98 % | $ 251 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
219 K | - | - | $ 55.5 M | USA |
 |
SCYNEXIS
SCYX
|
580 K | $ 0.78 | -2.71 % | $ 37.3 M | USA |
 |
Veru
VERU
|
268 K | $ 2.26 | -1.74 % | $ 305 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
922 K | $ 2.41 | -0.82 % | $ 25.2 M | USA |
 |
cbdMD
YCBD
|
452 K | $ 0.69 | -8.98 % | $ 2.98 M | USA |
 |
Viatris
VTRS
|
3.03 B | $ 15.89 | -1.48 % | $ 19.3 B | USA |